EU consultation open on research for “moonshot missions”

The European Commission is considering a “mission-oriented approach” to research policy, focusing part of the next multi-annual framework programme (FP9) on ambitious missions that can be readily embraced by the public. After commissioning several analyses of how this might work, the European Commission has now launched a general “Call for feedback on missions” regarding the criteria to be used for identifying missions and how missions should be implemented. Missions can be suggested as well, such as those focused poverty related and neglected diseases (PRND).

Website – EU

EU Global health R&D

Evaluation of Australia’s investment in PDPs supports TB and malaria as priorities

Australia’s Department of Foreign Affairs and Trade (DFAT) has released a review of its experience with product development partnerships (PDPs). It found that tuberculosis- (TB) and malaria-focused PDPs continue to be a priority. The TB Alliance; FIND, an international non-profit organisation that enables diagnostic tests for poverty-related diseases; and Medicines for Malaria Venture (MMV) were considered sound investment decisions.

The evaluation recommends Australia continue to focus on TB and malaria diagnostics and medicines and invest in vector control. DFAT management agreed with all 5 recommendations of the review.

Evaluation document – DFAT

Management response – DFAT

EDCTP to focus on co-infections and co–morbidities

A stakeholder meeting report of the European and Developing Countries Clinical Trial Partnership (EDCTP) urges long-term and more integrated management of poverty-related infectious diseases and non-communicable diseases (NCDs) to address co-infections and co-morbidities in low- and middle-income countries. EDCTP stakeholders report that the unique diagnostic, treatment and prevention challenges associated with these conditions decrease chances of recovery or cure and ultimately increase morbidity and mortality. Co-infections and co-morbidities will be a priority topic for EDCTP in 2018.

Website – EDCTP

Spain’s ISGlobal ranked as the third most influential global health think tank in Europe

According to the Lauder Institute’s “Global Go To Think Tank Index”, the Spanish health research center Barcelona Institute for Global Health (ISGlobal) has been ranked among the world’s ten most influential think tanks working in global health. ISGlobal has climbed up from the 16th place in 2016 to the 9th position in 2017. This ranks it the third most important global health institution in Europe and the only one not located in the United Kingdom.

Press release -ISGlobal

Spain Global health Global health R&D

Spanish think tank ISGlobal releases new report on SDG implementation

The Spanish think tank and research center Barcelona Institute for Global Health (ISGlobal) has released a new report analyzing the role of European health R&D institutions in furthering the sustainable development goals (SDGs) 2030 Agenda. Under the title “Health SDGs and Europe: the role of regional think tanks”, it suggests strengthening coordination and collaboration between research institutions and think tanks is essential to achieving the SDGs.

Press release - ISGlobal 

Swedish government provides core funding to new global health institute for 2018

The Swedish government has announced it will provide SEK1 million (US$120,000) in core funding to the Swedish Institute for Global Health Transformation, SIGHT, for the fiscal year 2018.

SIGHT is a global health institute that started in January 2017 under the auspices of the Royal Academy of Sciences. The purpose of SIGHT is to promote an interdisciplinary approach to strengthen and bridge collaborative policy work in the field of global health.

Press release – Swedish government (in Swedish) 

EDCTP and GHIT announce new partnership supporting product-development research

The Global Health Innovative Technology Fund (GHIT) and the European and Developing Countries Clinical Trials Partnership (EDCTP) have announced a new partnership to support product-development research. The partners’ first action will be to co-fund a clinical study that examines the use of a new tablet formulation to treat schistosomiasis, a parasitic disease, in preschool-aged children.

According to the announcement, EDCTP and GHIT are looking forward to co-funding research of mutual interest. Both organizations share a common funding scope covering HIV/AIDS, malaria, tuberculosis, and poverty-related infectious diseases.

Website – EDCTP

EDTCP calls for 2018 nominations recognizing outstanding contributions to health research

The European and Developing countries Clinical Trial Partnership (EDCTP) is seeking nominations recognizing outstanding individuals and research teams from Africa and Europe who have made significant contributions to health research in the following categories:

  • Scientific leadership;
  • Outstanding female scientist;
  • Outstanding research team;
  • The Dr. Pascoal Mocumbi Prize for scientists, policy-makers, or advocates for health and research aged 51 years and above.

In addition to scientific excellence, the awardees will have made major contributions to the EDCTP objectives of strengthening clinical research capacity in Africa, and supporting networking between developing and developed countries.

Nominations are open until February 28, 2018, 17:00 CET.

Website – EDCTP

European NGOs appeal for improved Council recommendations on EU research

European NGOs argue the European Council’s Committee of Permanent Representatives (COREPER I) has overlooked global health in its interim evaluation of the EU’s research program (Horizon 2020), which could impact planning around the next phase of the EU's research framework. The NGOs wrote a letter expressing their concerns on access to medicines. They called on the European Commission to increase the social impact of its medical research investments by ensuring complete transparency; improved measurement of social impact on health-related SDGs; promoting funding initiatives that focus on unmet public health needs; attaching equitable access conditions to public funding in health research; and linking open access and data requirements to publicly funded research.

Press release - Council of the EU

Letter -

EU Global health R&D

European Public Health Alliance calls for support for AMR statement

The European Public Health Alliance (EPHA) has issued, on behalf of a diverse group of public health organisations, a statement calling for eleven actions on antimicrobial resistance (AMR) that should be addressed by the European Commission and national executive agencies. These actions include, among others:

  1. Involve civil society in AMR-One Health policymaking;
  2. Support the development and implementation of National Action Plans and allocate adequate European funds to actions against AMR;
  3. Empower patients and raise public awareness.

All stakeholders interested in AMR are urged to sign the statement before January 10, 2018.

Website – EPHA

EU Global health Global health R&D